Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan-Feb;12(1):155-173.
doi: 10.1016/j.jceh.2021.08.017. Epub 2021 Aug 23.

A Current Understanding of Bile Acids in Chronic Liver Disease

Naba Farooqui  1 , Anshuman Elhence  2 , Shalimar  3
Affiliations
Review

A Current Understanding of Bile Acids in Chronic Liver Disease

Naba Farooqui et al. J Clin Exp Hepatol. 2022 Jan-Feb.

Abstract

Chronic liver disease (CLD) is one of the leading causes of disability-adjusted life years in many countries. A recent understanding of nuclear bile acid receptor pathways has increased focus on the impact of crosstalk between the gut, bile acids, and liver on liver pathology. While conventionally used in cholestatic disorders and to dissolve gallstones, the discovery of bile acids' influence on the gut microbiome and human metabolism offers a unique potential for their utility in early and advanced liver diseases because of diverse etiologies. Based on these findings, preclinical studies using bile acid-based molecules have shown encouraging results at addressing liver inflammation and fibrosis. Emerging data also suggest that bile acid profiles change distinctively across various causes of liver disease. We summarize the current knowledge and evidence related to bile acids in health and disease and discuss culminated and ongoing therapeutic trials of bile acid derivatives in CLD. In the near future, further evidence in this area might help clinicians better detect and manage liver diseases.

Keywords: AD, Acute decompensation; ALP, Alkaline phosphatase; AMACR, α-methylacyl-CoA racemase (AMACR); ASBT, Apical sodium dependent bile salt transporter; BA, Bile acid; BSEP, Bile salt export pump; BSH, Bile salt hydrolase; CA, Cholic acid; CDCA, Chenodeoxycholic acid; CLD; CLD, Chronic Liver Disease; CTP, Child-Turcotte-Pugh; CYP7A1, Cholesterol 7 α hydroxylase; DCA, Deoxycholic acid; DR5, Death receptor 5; ELF, Enhanced Liver Fibrosis; FGF-19, Fibroblast growth factor-19; FGFR4, FGF receptor 4; FXR, Farnesoid X receptor; GCA, Glycocholic acid; GDCA, Glycodeoxycholic acid; GLP-1, Glucagon-like peptide1; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HVPG, Hepatic Venous Pressure Gradient; LCA, Lithocholic acid; LPS, Lipopolysaccharide; MELD, Model for End-Stage Liver Disease (MELD); MRI-PDFF, Magnetic resonance imaging derived proton density fat fraction; NAFLD; NAFLD, Non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH, Nonalcoholic steatohepatitis; NTCP, Sodium taurocholate cotransporting polypeptide; OCA, Obeticholic acid; OST, Organic solute transporter; PBC, Primary biliary cirrhosis; PFIC, Progressive familial intrahepatic cholestasis; PSC, Primary sclerosing cholangitis; PXR, Pregnane X receptor; SHP, Small heterodimer partner; TBA, Total bile acids; TGR5, Takeda G-protein coupled receptor 5; TRAIL, TNF-related apoptosis-inducing ligand; UDCA, Ursodeoxycholic acid; UPLC-MS, Ultra-performance liquid chromatography with tandem mass spectrometry; VDR, Vitamin D receptor; bile acids; cirrhosis; microbiome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Enterohepatic cycle: Primary bile acids are synthesized predominantly via the classic pathway (80%) and secreted via bile salt export pump (BSEP) following conjugation with glycine and taurine. Following storage, in the gallbladder, they are released postprandially into the proximal small bowel. The secreted bile acids are actively absorbed via luminal apical sodium-dependent bile salt transporter (ASBT) in the distal small bowel from where they are transported to the portal circulation via organic solute transporter (OST). The reabsorbed bile acids are taken up by hepatocyte sinusoidal membrane protein sodium taurocholate cotransporting polypeptide (NTCP) and resecreted. The efficient enterohepatic cycling enables reabsorption of up to 95% of the bile acids and loss of around 5% of the pool which is resynthesized. CYP7A1: cytochrome P450 family 7 subfamily A member 1; FGF-19:fibroblast growth factor 19; FGFR4: fibroblast growth factor receptor 4; FXR: farnesoid X receptor.
Figure 2
Figure 2
Bile acid signaling via nuclear and surface receptors. CA: cholic acid; cAMP: cyclic adenosine monophosphate; CDCA: chenodeoxycholic acid; CYP7A1: cytochrome P450 family 7 subfamily A member 1; DCA: deoxycholic acid; FGF19: fibroblast growth factor 19; FGFR4: fibroblast growth factor receptor 4; FXR: farnesoid X receptor; GLP-1: glucagon-like peptide-1; LCA: lithocholic acid; PRK A: phosphoribulokinase A; SHP: small heterodimer partner; TGR-5: takeda-G-protein-receptor-5.
Figure 3
Figure 3
Effect of progression of cirrhosis on bile acids and microbiota.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The Top 10 Causes of Death. Accessed May 28, 2021. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
    1. Wong M.C.S., Huang J.L.W., George J., et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16:57–73. doi: 10.1038/s41575-018-0055-0. - DOI - PubMed
    1. Wong R.J., Aguilar M., Cheung R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555. doi: 10.1053/j.gastro.2014.11.039. - DOI - PubMed
    1. Pimpin L., Cortez-Pinto H., Negro F., et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718–735. doi: 10.1016/j.jhep.2018.05.011. - DOI - PubMed
    1. Bajaj J.S., Heuman D.M., Hylemon P.B., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940–947. doi: 10.1016/j.jhep.2013.12.019. - DOI - PMC - PubMed